Top

Drugs & Aging

Published in:

01-09-2009 | Review Article

Elderly Onset Rheumatoid Arthritis

Differential Diagnosis and Choice of First-Line and Subsequent Therapy

Authors: Juan Ignacio Villa-Blanco, Dr Jaime Calvo-Alén

Published in: Drugs & Aging | Issue 9/2009

Abstract

Elderly onset rheumatoid arthritis (EORA) has been considered a benign form of rheumatoid arthritis (RA). However, it most probably encompasses different subsets of patients with distinct outcomes. According to data reported in the most recent studies directly comparing older and younger RA patients, it seems that, overall, the prognosis of EORA patients is not very different from that of other patients with this disease. However, some cases with negative rheumatoid factor and polymyalgia-like symptoms appear to be a distinct subset with a different genetic basis and a more benign course.

The differential diagnosis of EORA from other rheumatological disorders that are prevalent in this stratum of the population, such as polymyalgia rheumatica, crystal-induced arthritis or osteoarthritis, may be complicated because these disorders can present with signs and symptoms similar to those of RA in some circumstances. A prompt diagnosis of true RA is important because early treatment should be implemented.

It is recommended that therapy of EORA be tailored according to disease activity, with the aim of achieving clinical remission or the lowest possible level of disease activity in order to minimize potential functional sequelae. Co-morbidities and drug toxicity profiles are major considerations when choosing the most suitable therapy for EORA patients. Prudent use and careful follow-up of all treatments are also required because of the increased risk of adverse events in elderly patients. However, no special contraindications to the use of disease-modifying antirheumatic drugs in this age group apply, and use of biological therapies currently used in younger RA patients has also been described in these patients. Therefore, a therapeutic strategy for first-line and subsequent treatment that is in accordance with the disease activity of patients with EORA is suggested.

Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States. Arthritis Rheum 2003; 48: 917–26PubMedCrossRef

Carbonell J, Cobo T, Descalzo MA, et al. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology 2008; 47(7): 1088–92PubMedCrossRef

Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 ACR criteria: a systematic review. Semin Arthritis Rheum 2006; 36: 182–8PubMedCrossRef

Laiho K, Tuomilehto J, Tilvis R. Prevalence of rheumatoid arthritis and musculoskeletal diseases in the elderly population. Rheumatol Int 2001; 20: 85–7PubMedCrossRef

Kent PD, Matteson EL. Clinical features and differential diagnosis. In: St Clair EW, Pisetsky DS, Haynes BF, editors. Rheumatoid arthritis. Philadelphia (PA): Lippincott Williams & Wilkins, 2004: 11–25

Symmonds DPM, Barrett EM, Bankhead CR, et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33: 735–9CrossRef

Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999; 42: 415–20PubMedCrossRef

Stastny P. Association of B cell alloantigen Drw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869–71PubMedCrossRef

Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205–13PubMedCrossRef

10.

Fries JF, Wolfe F, Apple R, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002; 46: 2320–9PubMedCrossRef

11.

Mattey DL, Hassell AB, Dawes PT, et al. Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1529–33PubMedCrossRef

12.

Weyand CM, Hicok KC, Conn DL, et al. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801–6PubMed

13.

Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. Seronegative rheumatoid arthritis in elderly and polymyalgia rheumatica have similar patterns of HLA association. J Rheumatol 2001; 28: 122–5PubMed

14.

Wu H, Khanna D, Park G, et al. Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age of onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis Rheum 2004; 50: 3093–103PubMedCrossRef

15.

Cecil RS, Krammerer WH. Rheumatoid arthritis in the aged. Am J Med 1951; 13: 439–45CrossRef

16.

Van Schaardenburg D, Breedweld FC. Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 1994; 23(6): 367–78PubMedCrossRef

17.

Kavanaugh AF. Rheumatoid arthritis in the elderly: is it a different disease? Am J Med 1997; 103(6A): 40S–8SPubMedCrossRef

18.

Deal CL, Meenan RD, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis. Arthritis Rheum 1985; 28: 987–94PubMedCrossRef

19.

Healey LA. Rheumatoid arthritis in the elderly. Clin Rheum Dis 1986; 12: 173–9PubMed

20.

Bajocchi G, La Corte R, Locaputo A, et al. Elderly onset rheumatoid arthritis: clinical aspects. Clin Exp Rheumatol 2000; 18Suppl. 20: S49–50PubMed

21.

Ferraccioli GF, Cavalieri F, Mercandati M, et al. Clinical features, scintiscan characteristics and x-ray progression of late onset rheumatoid arthritis. Clin Exp Rheumatol 1984; 2: 157–61PubMed

22.

Van der Heijde DMFM, van Reil PLCM, van Leeuwen MA, et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective follow-up study of early rheumatoid arthritis. J Rheumatol 1991; 18: 1285–9PubMed

23.

Pease CT, Bhakta BB, Devlin J, et al. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999; 38: 228–34CrossRef

24.

Calvo-Alén J, Corrales A, Sanchez-Andrada S, et al. Outcome of late-onset rheumatoid arthritis. Clin Rheumatol 2005; 24: 485–9PubMedCrossRef

25.

Bukhari M, Lunt M, Barton A, et al. Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Ann Rheum Dis 2007; 66: 389–93PubMedCrossRef

26.

Farragher TM, Goodson NJ, Naseem H, et al. Association of HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359–69PubMedCrossRef

27.

Naz SM, Farragher TM, Bunn DK, et al. The influence of age at symptom onset and length of follow-up on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008; 58: 985–9PubMedCrossRef

28.

Mackenzie AH. Differential diagnosis of rheumatoid arthritis. Am J Med 1988; 85Suppl. 4A: 2–11PubMedCrossRef

29.

Hoffman GS. Polyarthritis: the differential diagnosis of rheumatoid arthritis. Semin Arthritis Rheum 1978; 8(2): 115–41PubMedCrossRef

30.

Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin N Am 2007; 33: 57–70CrossRef

31.

Steinbach LS, Resnick D. Calcium pyrophosphate dehydrate crystal deposition disease revisited. Radiology 1996; 200(1): 1–9PubMed

32.

Arnett FC. Seronegative spondyloarthropathies. Bull Rheum Dis 1987; 37: 1–12PubMed

33.

Palazzi C, Olivieri I, Petricca A, et al. Rheumatoid arthritis or psoriatic symmetric polyarthritis: a difficult differential diagnosis. Clin Exp Rheumatol 2002; 20: 3–4PubMed

34.

Olivieri I, Palazzi C, Peruz G, et al. Management issues with elderly-onset rheumatoid arthritis: an update. Drugs Aging 2005; 22(10): 809–22PubMedCrossRef

35.

Dubost JJ, Sauvezie B. Late onset peripheral spondyloarthropathy. J Rheumatol 1989; 16: 1214–7PubMed

36.

Olivieri I, Salvarani C, Cantini F, et al. Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 2001; 13: 280–4PubMedCrossRef

37.

Bagratuni L. Prognosis in anarthritic rheumatoid syndrome. BMJ 1963; 1: 513–8PubMedCrossRef

38.

González-Gay MA, García-Porrúa C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in north-western Spain. J Rheumatol 2000 Sep; 27(9): 2179–84PubMed

39.

González-Gay MA, García-Porrúa C, Salvarani C, et al. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol 1999 May–Jun; 17(3): 276–8PubMed

40.

Dimant J. Rheumatoid arthritis in the elderly presenting as polymyalgia rheumatica. J Am Geriatr Soc 1979; 27: 183–5PubMed

41.

Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988; 15: 750–2PubMed

42.

Hunder GG, Gorozny J, Weyland C. Is seronegative RA in the elderly the same as polymyalgia rheumatica? Bull Rheum Dis 1994; 43: 1–3PubMed

43.

López-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004; 43: 655–7CrossRef

44.

Lange U, Piegsa M, Teichmann J, et al. Ultrasonography of the glenohumeral joints: a helpful instrument in differentiation in elderly onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatol Int 2000; 19: 185–9PubMedCrossRef

45.

Cantini F, Salvarani C, Niccoli L, et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J Rheumatol 2004; 31: 120–4PubMed

46.

Ehrlich GE. Erosive osteoarthritis: presentation, clinical pearls, and therapy. Curr Rheumatol Rep 2001; 3(6): 484–8PubMedCrossRef

47.

McCarty DJ, ÓDuffy JD, Pearson L, et al. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985; 254: 2753–7

48.

Russell EB, Hunter JB, Pearson L, et al. Remitting, seronegative, symmetrical synovitis with pitting edema: 13 additional cases. J Rheumatol 1990; 17: 633–9PubMed

49.

Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol 1999; 26: 115–20PubMed

50.

Caldwell DS, McCallum RM. Rheumatologic manifestation of cancer. Med Clin North Am 1986; 70: 385–417PubMed

51.

Stummvoll GH, Aringer M, Machold KP, et al. Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasm: report of two cases and review of the literature. Scand J Rheumatol 2001; 30: 40–4PubMedCrossRef

52.

Pease C, Keat A. Arthritis as the main or the only symptom of hepatitis B infection. Postgrad Med J 1985; 61(716): 545–7PubMedCrossRef

53.

Zuckerman E, Keren D, Rozembaun M, et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 2000; 18(5): 579–84PubMed

54.

Studenski SA, Ward MM. Pharmacology and the elderly. In: Harris Jr ED, Budd RC, Firestein GS, et al., editors. Kelley’s textbook of rheumatology. 7th ed. Philadelphia (PA): Elsevier Saunders, 2005: 961–6

55.

Walker J, Wynne H. The frequency and severity of adverse drug reactions in older people. Age Ageing 1994; 23: 255–9PubMedCrossRef

56.

Bird HA. Drugs and the elderly. Ann Rheum Dis 1990; 49: 1021–4PubMedCrossRef

57.

Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007; 21: 27–42PubMedCrossRef

58.

Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19: 163–77PubMedCrossRef

59.

Machold KP, Stamm TA, Eberl GJM, et al. Very recent onset arthritis: clinical, laboratory and radiological findings during the first year of disease. J Rheumatol 2002; 29: 2278–87PubMed

60.

Van der Heide A, Jacobs JWG, Bjilsma JWJ, et al. The effectiveness of early treatment with “second line” anti-rheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124(8): 699–707PubMed

61.

Stenger AA, van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37: 1157–63PubMedCrossRef

62.

Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446–51PubMedCrossRef

63.

Nell V, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906–17CrossRef

64.

Anderson JJ, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22–9PubMedCrossRef

65.

Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 1367–74CrossRef

66.

Castro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol 2008; 20: 314–9PubMedCrossRef

67.

Smolen JS, van der Heijde DMFM, St Clair W. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702–10PubMedCrossRef

68.

Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis. Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(1): 34–45PubMedCrossRef

69.

Bressolle F, Bologna C, Kinowski JM, et al. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis: a comparison with young patients. J Rheumatol 1997; 24(10): 1903–9PubMed

70.

Kristensen LO, Weismann K, Hutters L. Renal function and the rate of disappearance of methotrexate from serum. Eur J Clin Pharmacol 1975; 8: 439–44PubMedCrossRef

71.

Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992; 35(10): 1117–25PubMedCrossRef

72.

Wernick R, Smith DL. Central nervous system toxicity associated with weekly low dose methotrexate therapy. Arthritis Rheum 1989; 32: 770–5PubMedCrossRef

73.

MacKinnon SK, Starkebaum G, Wilkens RF. Pancytopenia associated with low dose pulse methotrexate therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985; 15: 119–26PubMedCrossRef

74.

Weinblatt ME. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003; 62 Suppl. ii: ii94–6PubMed

75.

Smolen JS, Sokka T, Pincus T, et al. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21Suppl. 31: S209–10PubMed

76.

Grigor C, Capell HA, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–9PubMedCrossRef

77.

Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995; 7(6): 420–37PubMedCrossRef

78.

Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991; 18(7): 973–7PubMed

79.

Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging 2003; 20: 723–36PubMedCrossRef

80.

Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicenter trial. European Leflunomide Study Group. Lancet 1999; 353: 259–66PubMedCrossRef

81.

Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations though a process of consensus. Rheumatology (Oxford) 2005; 44: 280–6CrossRef

82.

Hurst S, Kallan MJ, Wolfe F, et al. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002; 29: 1639–45PubMed

83.

Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000959

84.

Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110: 1321–6PubMedCrossRef

85.

Rigaudiere F, Ingster-Moati I, Hache JC, et al. Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment [in French]. J Fr Ophthalmol 2004; 27: 191–4CrossRef

86.

O’Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Arthritis Rheum 2002; 46(5): 1164–70PubMedCrossRef

87.

Choy EHS, Smith C, Doré CJ, et al. A meta-analysis of the efficacy and toxicity of combining disease-modifying antirheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005; 44: 1414–21PubMedCrossRef

88.

Dale J, Alcorn N, Capell H, et al. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheum 2007; 3(8): 450–8CrossRef

89.

Svartz N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 1948; 4: 56–60

90.

Taggart AJ, McDermott B, Delargy M, et al. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. Scand J Rheumatol Suppl 1987; 64: 29–36PubMedCrossRef

91.

Haagsma CJ. Clinically important drug interactions with disease-modifying antirheumatic drugs. Drugs Aging 1998; 13(4): 281–9PubMedCrossRef

92.

Pinals RS, Kaplan SB, Lawson JG, et al. Sulfasalazine in rheumatoid arthritis: a double blind, placebo-controlled trial. Arthritis Rheum 1986; 29(12): 1427–34PubMedCrossRef

93.

Suarez-Almazor ME, Belseck E, Shea B, et al. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000958

94.

Verstappen SM, Jacobs JW, van de Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443–9PubMedCrossRef

95.

Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 306–13PubMedCrossRef

96.

Le Loet X, Berthelot JM, Cantagrel A, et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006; 65(1): 45–50PubMedCrossRef

97.

Meyer O, De Bandt M, Berthelot JM, et al. Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months’ first line DMARD therapy. Joint Bone Spine 2007; 74(1): 73–8PubMedCrossRef

98.

Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52: 3360–70PubMedCrossRef

99.

Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142–6PubMedCrossRef

100.

Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radio-graphic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371–80PubMedCrossRef

101.

Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007; 66Suppl. III: iii2–22PubMedCrossRef

102.

Genevay S, Finckh A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis-alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 57: 679–85PubMedCrossRef

103.

Ornetti P, Chevillotte H, Zerrak A, et al. Anti-tumor necrosis-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. Drugs Aging 2006; 23(11): 855–60PubMedCrossRef

104.

Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007; 24(3): 239–54PubMedCrossRef

105.

Van der Kooij SM, Allart CF, Dijkmans BAC, et al. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 287–94PubMedCrossRef

106.

Van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007; 56: 2129–34PubMedCrossRef

107.

Lee SJ, Reed G, Soto L, et al. Persistence of clinical benefit in rheumatoid arthritis after discontinuation of TNF-inhibitor therapy: analysis from the CORRONA database [abstract]. Arthritis Rheum 2007; 56: S311CrossRef

Title: Elderly Onset Rheumatoid Arthritis
Differential Diagnosis and Choice of First-Line and Subsequent Therapy
Authors: Juan Ignacio Villa-Blanco
Dr Jaime Calvo-Alén
Publication date: 01-09-2009
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 9/2009
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/11316740-000000000-00000

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2009

NSAID Use and the Risk of Parkinson’s Disease

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing

Immunotherapy in Elderly Transplant Recipients

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting

Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials